These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 10875231

  • 1. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
    Cipriano SC, Chen L, Kumar TR, Matzuk MM.
    Endocrinology; 2000 Jul; 141(7):2319-27. PubMed ID: 10875231
    [Abstract] [Full Text] [Related]

  • 2. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
    Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC, Matzuk MM.
    Mol Endocrinol; 1999 Jun; 13(6):851-65. PubMed ID: 10379885
    [Abstract] [Full Text] [Related]

  • 3. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
    Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM.
    Mol Endocrinol; 1996 May; 10(5):534-43. PubMed ID: 8732684
    [Abstract] [Full Text] [Related]

  • 4. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
    Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM.
    Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SMAD3 regulates gonadal tumorigenesis.
    Li Q, Graff JM, O'Connor AE, Loveland KL, Matzuk MM.
    Mol Endocrinol; 2007 Oct; 21(10):2472-86. PubMed ID: 17595316
    [Abstract] [Full Text] [Related]

  • 7. Role of androgens in testicular tumor development in inhibin-deficient mice.
    Shou W, Woodruff TK, Matzuk MM.
    Endocrinology; 1997 Nov; 138(11):5000-5. PubMed ID: 9348231
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma.
    Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3720-7. PubMed ID: 9360531
    [Abstract] [Full Text] [Related]

  • 12. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development.
    Matzuk MM, Kumar TR, Shou W, Coerver KA, Lau AL, Behringer RR, Finegold MJ.
    Recent Prog Horm Res; 1996 Nov; 51():123-54; discussion 155-7. PubMed ID: 8701077
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overexpression of mouse follistatin causes reproductive defects in transgenic mice.
    Guo Q, Kumar TR, Woodruff T, Hadsell LA, DeMayo FJ, Matzuk MM.
    Mol Endocrinol; 1998 Jan; 12(1):96-106. PubMed ID: 9440814
    [Abstract] [Full Text] [Related]

  • 15. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice.
    Kumar TR, Wang Y, Matzuk MM.
    Endocrinology; 1996 Oct; 137(10):4210-6. PubMed ID: 8828479
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.